Abstract:The purpose of the research is to examine the advantages and difficulties of target-site drug delivery methods, with an emphasis on the application of polyethylene glycol (PEG) to enhance drug solubility, bioavailability, and immune response characteristics. It has been demonstrated that this method lowers immunogenicity, enhances pharmacokinetics, and helps drugs pass the blood-brain barrier while reducing reticuloendothelial system clearance. PEG and its derivatives are being used more and more to alter therapeutic substances, offering an escape from some of the drawbacks of conventional medication formulations. In the review, different PEGylation tactics are examined, including cutting-edge methods for reversing multi-drug resistance in nanocarriers. PEGylation has a number of benefits, but there are still drawbacks, including the immunogenic reaction to PEG, which is sometimes referred to as "anti-PEG antibodies," and stability problems that call for the creation of countermeasures. The study devotes a large amount of its space to listing FDA-approved PEGylated medications, emphasizing their therapeutic advantages and clinical uses in a range of medical specialties. The research also explores the regulatory environment that surrounds PEG, closely examining its effectiveness and safety in medication compositions. The review goes beyond PEGylation and includes lipid-based nanocarriers, including liposomes, nanostructured lipid carriers (NLCs), and solid lipid nanoparticles (SLNs). Because these nanocarriers can target specific tissues or cells, improve bioavailability, and encapsulate pharmaceuticals, they are becoming more and more significant in drug delivery systems. The Target Product Profile (TPP) and Quality by Design (QbD) principles serve as the foundation for the creation and characterization of these lipid-based systems. These tools direct the methodical assessment of material properties and risk assessments during the formulation phase. This method guarantees that the finished product satisfies the appropriate requirements for efficacy, safety, and quality. The regulatory status and safety profile of nano lipid carriers are covered in the paper's conclusion, which emphasizes the importance of careful examination and oversight in bringing these cutting-edge products to market. Overall, this thorough analysis highlights the revolutionary potential of lipid-based nanocarriers and PEGylation in improving drug delivery and therapeutic efficacy, but it also draws attention to the continued difficulties and legal issues that need to be resolved in order to fully reap the benefits of these technologies in biomedicine.

The Technique and Clinical Development of Site-specific PEGylated Protein Drugs

Site-specific PEGylation Strategies and Suitable Modified Sites of Protein Drugs

Site-Specific PEGylation of Protein Drugs

Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)

PROGRESS RESEARCH OF IN PEG MODIFIED DRUGS

PEGylated therapeutics in the clinic

PEG Modification of Protein Drug

Current drug research on PEGylation with small molecular agents

Advances in PEGylation of Drug Conjugates

Advances in PEGylation in Drug Delivery Systems

Advances in PEGylated targeted nano-preparation

PEGylation in Pharmaceutical Development: Current Status and Emerging Trends in Macromolecular and Immunotherapeutic Drugs

Drug Development Through Modification of Small Molecular Drugs with Monodisperse Poly(ethylene Glycol)s

Discrete Polyethylene Glycol Derivatives As a Potent Impetus for Next-Generation Biomedicines

The Effect of PEG-modification on the Pharmacokinetics of Protein and the Related Pharmacokinetic Research Methods

Site-Directed Modification of Genetically Engineered Proteus Sp Lipase K107 Variants with A Polyethylene Glycol Derivative

Recent advances in the bioanalytical methods of polyethylene glycols and PEGylated pharmaceuticals

Quantitatively fine-tuning the physicochemical and biological properties of peptidic polymers through monodisperse PEGylation.

In vivo metabolism and safety evaluation of PEGylated proteins drugs

Structure-Based Site-Specific PEGylation of Fibroblast Growth Factor 2 Facilitates Rational Selection of Conjugate Sites.

Pegylated Drug Delivery Systems: from Design to Biomedical Applications